Recently, we evaluated the performance of 190 candidate protein biomarkers to discriminate between patients with benign or malignant lung nodules. The candidate markers came from the substantial literature on cancer-associated proteins as well as from mass spectrometry studies, conducted in-house to identify proteins up-regulated either on the surface of tumors or in the secretome of tumors, as compared to adjacent normal lung tissue. Plasma samples were obtained retrospectively for analysis from those with either benign or malignant nodules. A 13 protein panel was identified with a high negative predictive value, able to remove approximately half of those with benign nodules from further consideration. The test has been commercialized, using MRM mass spectrometry, by Integrated Diagnostics.
Creating a Clinical Diagnostic Test from Discovery Through Launch with Mass Spectrometry
Video Apr 14, 2015
Recommended Videos
Dynamic Light Scattering (DLS) is a technique classically used for measuring the size of particles typically in the sub-micron region, dispersed in a liquid. The sensitivity of some modern systems is such that it can also now be used to measure the size of macromolecules in solution.
WATCH NOWScientists from the University of Bristol, CNRS and Imophoron Ltd worked with the computer technology giant Oracle to develop a new kind of vaccine that needs no refrigeration. They used synthetic biology, cryo-electron microscopy and high-performance cloud computing to produce a candidate vaccine against the mosquito-borne chikungunya virus. Their findings could revolutionise the way vaccines are designed, developed and stored.
WATCH NOWLike what you just watched? You can find similar content on the communities below.
Analysis & Separations Diagnostics Proteomics & MetabolomicsTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
